🔍

Jagsonpal Pharmaceuticals Limited (JAGSNPHARM)

₹218.37 -0.33% last close, 16 Oct

📊 NSE: JAGSNPHARM 🏢 Pharmaceuticals - Indian - Bulk Drugs & Formln 📢 Latest filing: 01 Oct 2026 📝 Analysis written: 14 Dec 2025

Latest quarterly results (Q1 FY27)

In its latest reported quarter, Q1 FY27, Jagsonpal Pharmaceuticals' revenue was ₹82.2 Cr, and net profit ₹13.2 Cr; the operating margin was 21.0%.

Q1 FY27 (₹ Cr)	Value	YoY	QoQ
Revenue	₹82.2	—	—
Operating profit	₹17.2	—	—
Net profit	₹13.2	—	—
EPS (₹)	2.00	—	—
Operating margin	21.0%	—	—

Full quarterly financials → Results calendar →

JAGSNPHARM delivery percentage and bulk deals

NSE end-of-day data for Fri, 16 Oct 2026

On Fri, 16 Oct 2026, 62.46% of the JAGSNPHARM shares traded on NSE were taken to delivery, against the stock's own 20-session average of 48.82%. Delivery was unusually high while the price barely moved (-0.33%). Volume was 0.1 times its average, well below normal. 4 bulk or block deals were reported in JAGSNPHARM in the last 60 days: ₹18 Cr bought and ₹18 Cr sold.

62.46%Delivery, 16 Oct

48.82%Own 20-session average

0.1×Volume vs its average

₹218.37NSE close · -0.33%

Delivery in the last 5 sessions: 54.3% · 61.7% · 50.4% · 61.2% · 62.5%

Date	Side	Counterparty	Value	Price	Quantity	Type
24 Sep	Sell	Nk Securities Research Private Limited	₹10.22 Cr	₹241.20	423,870	Bulk
24 Sep	Buy	Nk Securities Research Private Limited	₹10.22 Cr	₹241.03	423,870	Bulk
24 Sep	Sell	Blitzquant Research Llp	₹8.06 Cr	₹242.74	331,971	Bulk
24 Sep	Buy	Blitzquant Research Llp	₹8.05 Cr	₹242.60	331,971	Bulk

Delivery across the market →All bulk and block deals →

A description of what the exchange published, not a recommendation. Names such as "accumulation" or "long buildup" label a pattern in the numbers. How delivery is analysed

📢 Recent Corporate Announcements

Jagsonpal Acquires Group Pharma's Wellness Portfolio for Up to ₹46.7 Cr

🟢 POSITIVE ⭐ 8/10

M&A 📅 01 Oct 2026, 05:00 PM

Jagsonpal Pharmaceuticals has consummated the acquisition of the Wellness Portfolio of Group Pharmaceuticals Limited effective October 1, 2026. The deal involves an upfront consideration of ~₹23.7 Cr and deferred earnouts of up to ~₹23.0 Cr linked to FY28 sales performance. The acquired portfolio generated ₹24.6 Cr in FY26 net revenue with ~78% gross margins and brings two key brands (Hemozink and Sudin) across 6 states. The transaction adds roughly 15.9% to Jagsonpal's TTM revenue of ₹155 Cr, funded comfortably via existing cash reserves of over ₹100 Cr.

Upfront consideration of ~₹23.7 Cr with up to ~₹23.0 Cr in additional deferred consideration linked to FY28 sales
Acquired portfolio reported FY26 net revenue of ~₹24.6 Cr with ~78.0% gross margin
Adds ~30,000 doctor reach, ~125 field force, and 2 key brands (Hemozink and Sudin) across 6 SKUs
Company holds robust liquidity with cash balance exceeding ₹100 Cr (reported ~₹170 Cr as of Q1 FY27)

💡 Monitor upcoming quarterly financials to track integration speed, gross margin accretiveness, and contribution toward the management's target of ₹500 Cr topline.

Jagsonpal Pharma Allots 1,01,825 Equity Shares Under ESOP 2022

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 30 Sep 2026, 04:09 PM

Jagsonpal Pharmaceuticals has allotted 1,01,825 equity shares of face value Rs 2 each to eligible employees under its JPL ESOP 2022. The allotment comprises 1,00,000 shares exercised at Rs 94.00 per share and 1,825 shares at Rs 115.60 per share. As a result, the paid-up share capital increased marginally from Rs 13,19,14,840 to Rs 13,21,18,490 across 6,60,59,245 shares. The dilution is negligible at approximately 0.15% of the total equity base.

Allotment of 1,01,825 equity shares of Rs 2 each under JPL ESOP 2022
Exercise price set at Rs 94.00 for 1,00,000 shares and Rs 115.60 for 1,825 shares
Paid-up share capital expands from Rs 13,19,14,840 to Rs 13,21,18,490
Total issued shares rise from 6,59,57,420 to 6,60,59,245

💡 Track subsequent listing approvals and upcoming quarterly earnings to monitor underlying operating performance.

Jagsonpal to Acquire Group Pharma's Wellness Portfolio for Up to ₹46.7 Cr

🟢 POSITIVE ⭐ 8/10

M&A 📅 23 Sep 2026, 06:03 PM

Jagsonpal Pharmaceuticals has entered into a Business Transfer Agreement to acquire the Wellness Portfolio of Group Pharmaceuticals via a slump sale. The deal involves an initial upfront cash consideration of ₹23.7 crore and an earnout of up to ₹23.0 crore linked to FY28 sales, capping total consideration at ₹46.7 crore. The acquired portfolio recorded a turnover of ₹24.6 crore in FY25-26, representing approximately 15.9% of Jagsonpal's TTM revenue (₹155 crore). The transaction is slated for completion on or before November 1, 2026, strengthening its women's healthcare and wellness footprint.

Acquisition of Wellness Portfolio via slump sale with total capped consideration of ₹46.7 crore
Upfront cash consideration of ₹23.7 crore at closing, with performance earnouts up to ₹23.0 crore linked to FY 2027-28 sales
Target portfolio delivered ₹24.6 crore turnover in FY 2025-26 (~15.9% of Jagsonpal's TTM revenue)
Closing expected on or before November 1, 2026, subject to customary closing conditions

💡 Track the completion of closing conditions by November 1, 2026, and watch for margin accretion and revenue integration progress in subsequent quarterly earnings.

Jagsonpal to Acquire Group Pharma's Wellness Portfolio for Up to ₹46.7 Cr

🟢 POSITIVE ⭐ 8/10

M&A 📅 23 Sep 2026, 05:57 PM

Jagsonpal Pharmaceuticals has signed a Business Transfer Agreement to acquire the Wellness Portfolio of Group Pharmaceuticals via a slump sale on a going-concern basis. The deal entails an initial payout of ₹23.7 crores upon closing and an earnout of up to ₹23.0 crores tied to FY 2027-28 sales performance, capping total consideration at ₹46.7 crores. The acquired portfolio recorded a turnover of ₹24.6 crores in FY 2025-26, representing approximately 15.9% of Jagsonpal's TTM revenue of ₹155 crores. The transaction strengthens the company's presence in women's healthcare and is slated for completion on or before November 1, 2026.

Acquisition consideration includes ₹23.7 crores upfront plus up to ₹23.0 crores performance-linked payout, capped at ₹46.7 crores
Acquired portfolio turnover was ₹24.6 crores in FY 2025-26 (~15.9% of Jagsonpal's TTM revenue)
Closing expected on or before November 1, 2026, subject to conditions precedent
Transaction conducted via slump sale on a going-concern basis with zero related-party involvement

💡 Track the completion of customary conditions precedent by the November 1, 2026 target closing date and monitor revenue contribution and margin impact in subsequent quarterly disclosures.

Jagsonpal Pharma Shareholders Approve All 5 AGM Resolutions With Over 99.9% Majority

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 21 Sep 2026, 05:07 PM

Jagsonpal Pharmaceuticals Limited announced the voting results and scrutinizer's report for its 47th Annual General Meeting held on September 18, 2026. All five resolutions were passed with overwhelming shareholder approval (>99.9% in favor), including the adoption of FY2026 audited financial statements and declaration of dividend. Other approved items included the reappointment of director Mr. Prithipal Singh Kochhar, ratification of cost auditor remuneration, and the appointment of Mr. Anil Kumar Matai as an Independent Director. Overall voter turnout stood at 74.66% of total shares, representing 49,243,235 votes polled.

All 5 resolutions passed with over 99.9% favorable votes
Overall voter participation stood at 74.66% (49,243,235 votes polled)
3,030,400 votes cast by relative Mr. Rajpal Singh Kochhar were declared invalid for Resolution 3 due to related-party interest
Appointment of Mr. Anil Kumar Matai as Independent Director approved via special resolution with 99.99% votes in favor

💡 Track subsequent corporate disclosures for the disbursement timeline of the FY2026 dividend and monitor Q2 FY2027 earnings releases.

Jagsonpal Pharmaceuticals Concludes 47th AGM; Scrutinizer Results Awaited Within 2 Days

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 18 Sep 2026, 05:20 PM

Jagsonpal Pharmaceuticals Limited held its 47th Annual General Meeting (AGM) on September 18, 2026, via video conferencing. Key resolutions transacted included the adoption of FY26 financial statements, dividend declaration for FY26, director reappointment, and the appointment of an Independent Director. Detailed voting results and the scrutinizer's report will be declared within 2 working days.

47th AGM held on September 18, 2026 (commenced at 3:30 p.m. and concluded at 4:04 p.m.)
Remote e-voting was conducted from September 14, 2026 (9:00 AM) to September 17, 2026 (5:00 PM)
Transacted 5 resolutions including FY26 dividend declaration and appointment of Anil Kumar Matai as Independent Director
Consolidated Scrutinizer's Report to be announced within 2 working days of the meeting

💡 Monitor stock exchange filings over the next 2 working days for the final scrutinizer's voting results to confirm resolution approvals.

Jagsonpal Pharma Sets Sept 4 Dividend Record Date; 47th AGM on Sept 18, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 27 Aug 2026, 08:21 PM

Jagsonpal Pharmaceuticals Limited has issued the notice for its 47th Annual General Meeting scheduled for September 18, 2026, and published its Annual Report for FY25-26. The record date for determining dividend eligibility has been fixed as September 04, 2026, with remote e-voting running from September 14 to September 17, 2026. In the accompanying Annual Report overview, the company highlighted FY26 revenue of ₹2,872 mn (up 6.9% YoY), operating PAT of ₹446 mn (up 19% YoY), and total shareholder return exceeding ₹650 mn via buybacks and dividends. The report also highlights the inorganic acquisition of an 85% stake in Aequitas Healthcare (₹53 cr revenue in FY26).

47th AGM scheduled for September 18, 2026; remote e-voting open from September 14 to September 17, 2026.
Record date for payment of dividend fixed as September 04, 2026.
FY26 revenue reported at ₹2,872 mn and operating PAT at ₹446 mn with ₹614 mn free cash flow.
Shareholder distributions exceeded ₹650 mn in FY26, including a ₹400 mn buyback and 200% dividend (including 75% special dividend).
Acquired an 85% stake in Aequitas Healthcare Private Limited (FY26 revenue of ₹53 cr) to enter institutional hospital channels.

💡 Investors seeking dividend payout must hold shares prior to the September 04, 2026 record date; monitor voting outcomes following the AGM on September 18, 2026.

Jagsonpal Pharma: 47th AGM Scheduled for Sept 18, 2026; Web-Link for Annual Report Sent

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 27 Aug 2026, 05:41 PM

Jagsonpal Pharmaceuticals Limited has issued letters to shareholders whose email addresses are not registered, providing web-links to access the Annual Report and AGM Notice for FY 2025-26. The 47th Annual General Meeting (AGM) is scheduled to be held on Friday, September 18, 2026, at 3:30 PM IST via Video Conferencing. The notice follows the board's meeting notice dated July 29, 2026. This is a standard statutory compliance filing under SEBI LODR Regulation 36(1)(b).

47th Annual General Meeting scheduled for Friday, September 18, 2026, at 3:30 PM IST via Video Conferencing
Web-link provided to unregistered email holders under Regulation 36(1)(b) of SEBI LODR
AGM Notice originally dated July 29, 2026
Annual Report 2025-26 and voting details made accessible on company website

💡 Shareholders can access the FY 2025-26 Annual Report on the company's portal to review detailed financial performance, dividend proposals, and AGM resolutions ahead of the September 18, 2026 meeting.

Jagsonpal Pharma Allots 27,950 Equity Shares Under ESOP 2022

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 24 Aug 2026, 11:56 AM

Jagsonpal Pharmaceuticals has allotted 27,950 equity shares of face value Rs 2 each to eligible employees following the exercise of stock options under JPL ESOP 2022. The allotment increases the company's paid-up share capital from Rs 13.19 crore (6,59,29,470 shares) to Rs 13.19 crore (6,59,57,420 shares). The options were exercised at strike prices of Rs 94.00 (6,800 shares), Rs 113.60 (6,750 shares), and Rs 115.60 (14,400 shares). The overall equity dilution is negligible at approximately 0.04% of total share capital.

Allotted 27,950 equity shares of Rs 2 face value under JPL ESOP 2022
Paid-up equity share capital expands marginally from 6,59,29,470 to 6,59,57,420 shares
Exercise prices range across Rs 94.00, Rs 113.60, and Rs 115.60 per share
Resulting equity dilution is negligible at ~0.04% of total share capital

💡 Track regular quarterly performance and management execution on new product launches; no specific action required for this routine administrative filing.

Jagsonpal Q1 FY27: 22% PAT Growth and Rs 25 Cr Aequitas Healthcare Acquisition

🟢 POSITIVE ⭐ 7/10

EARNINGS 📅 04 Aug 2026, 04:23 PM

Jagsonpal Pharmaceuticals (JPL) reported a strong Q1 FY27 with 9% sales growth and 22% PAT growth, outperforming the industry growth rate of 11.6% by reaching 18.9% (Pharmarack data). The company completed the acquisition of Aequitas Healthcare for an enterprise value of Rs 25 crore, providing entry into the hospital segment with a business that generated Rs 53 crore in FY26. A Rs 40 crore share buyback was also concluded, which improved the Return on Capital Employed (ROCE) by 340 bps. Management is pivoting the portfolio toward high-margin semi-chronic and specialty therapies while maintaining an asset-light, outsourced manufacturing model.

Q1 FY27 PAT grew by 22% and Operating EBITDA increased by 21% year-on-year.
Acquired Aequitas Healthcare at an enterprise value of Rs 25 crore, adding Rs 53 crore in annual revenue (FY26).
Completed a Rs 40 crore share buyback at a 40% premium, which was oversubscribed 3.67 times.
Power brand portfolio grew by 19% compared to the broader market growth of 16%.
Inventory turnover ratio improved significantly to 17.6 in FY25 from 13.9 in FY24.

💡 Investors should monitor the integration of Aequitas Healthcare, specifically how it impacts overall gross margins given the lower-margin nature of hospital-segment sales. Watch for the company's ability to maintain its target of 1.5x industry growth through its new specialty therapy launches.

9% Q1 Revenue Growth and Rs 25 Cr Aequitas Acquisition to Drive Hospital Segment Entry

🟢 POSITIVE ⭐ 7/10

EARNINGS 📅 04 Aug 2026, 04:20 PM

Jagsonpal Pharmaceuticals (JPL) reported a 9% sales growth for Q1 FY27, with EBITDA and PAT growing faster at 21% and 22% respectively. A key highlight is the Rs 25 Cr acquisition of Aequitas Healthcare, which brings Rs 53 Cr in FY26 revenue and provides immediate access to the hospital segment. The company also completed a Rs 40 Cr share buyback, which was oversubscribed 3.67x and improved ROCE by 340 bps. Management aims to maintain growth at 1.5x the industry rate by shifting focus toward high-margin semi-chronic and specialty therapies.

Q1 FY27 sales grew 9%, while operating EBITDA and Net Profit increased by 21% and 22% respectively.
Acquired Aequitas Healthcare for an enterprise value of Rs 25 Cr, representing ~34% of JPL's TTM revenue.
JPL's Pharmarack growth of 18.9% significantly outperformed the industry growth of 11.6% during the quarter.
Completed a Rs 40 Cr share buyback at a 40% premium to the then-market price, improving capital efficiency.
Power brand portfolio grew at 19% vs market growth of 16%, with 5 brands now ranking #1 in their molecules.

💡 Investors should monitor the integration of Aequitas Healthcare, specifically how it impacts overall gross margins given the lower-margin nature of the hospital segment. Watch for the execution of the 'semi-chronic' shift and whether the company can sustain its 1.5x industry growth target.

Jagsonpal Pharmaceuticals Releases Q1 FY27 Earnings Call Audio Recording

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 30 Jul 2026, 05:30 PM

Jagsonpal Pharmaceuticals has made the audio recording of its Q1 FY27 earnings conference call available to the public following the session held on July 30, 2026. The company currently operates with a market capitalization of ₹1,512 Cr and a high P/E ratio of 138.0, reflecting significant growth expectations. Investors should note the company's asset-light model, which relies on outsourced manufacturing and strategic brand acquisitions like Yash Pharma. The call likely addressed the company's strategy to outpace the Indian Pharmaceutical Market growth rate of 7.5%.

Earnings conference call for Q1 FY27 held on July 30, 2026, at 2:30 P.M.
Promoter holding remains stable at 69.36% as of June 2026.
Company reported TTM revenue of ₹73 Cr with an operating profit margin of 22.3%.
Top 5 brands contribute approximately 54% of total revenue, indicating high brand concentration.

💡 Investors should access the recording to understand management's guidance on MR productivity and the integration progress of the Yash Pharma acquisition.

Jagsonpal Pharmaceuticals Designates Two New Senior Management Personnel

🟡 NEUTRAL ⭐ 3/10

MANAGEMENT 📅 29 Jul 2026, 06:48 PM

Jagsonpal Pharmaceuticals has designated two existing employees as Senior Management Personnel (SMP) effective July 29, 2026, following an internal restructuring. Mr. Balmukund Keshav (DGM - IT), with 17 years at the company, and Mr. Sanjay Singhal (GM - CQA & Regulatory Affairs), with the company since 2020, have been elevated to these roles. This move formalizes leadership in critical operational areas like digital transformation and regulatory compliance for the ₹1,512 Cr market cap company. The change is administrative and does not involve new external hires.

Mr. Balmukund Keshav designated as SMP with 29 years of total IT experience and 17 years at the company.
Mr. Sanjay Singhal designated as SMP with 31 years of pharmaceutical industry experience.
Designations are effective as of July 29, 2026, following internal restructuring.
Mr. Singhal has been associated with the company since March 11, 2020, and is a government-approved technical person for all dosage forms.

💡 No immediate action required as these are internal redesignations; investors should monitor if this restructuring improves the execution of the company's asset-light growth strategy.

1,20,000 ESOPs Granted at Rs 179.25 Exercise Price

🟡 NEUTRAL ⭐ 3/10

MANAGEMENT 📅 29 Jul 2026, 06:34 PM

Jagsonpal Pharmaceuticals has approved the grant of 1,20,000 stock options to employees under its 2022 ESOP plan. The exercise price is set at Rs 179.25, which represents a discount of approximately 22% compared to the current market price of Rs 230.5. These options will vest in four equal annual installments (25% each) starting from July 2027. The total potential equity dilution from this specific grant is minimal at approximately 0.18% of the current share capital.

Grant of 1,20,000 employee stock options approved on July 29, 2026
Exercise price fixed at Rs 179.25 per option, significantly below the current market price of Rs 230.5
Vesting schedule set for 4 equal annual tranches starting from the first anniversary of the grant
Potential equity dilution estimated at ~0.18% based on the current market capitalization of Rs 1,512 Cr

💡 Monitor the 'Employee Benefit Expenses' in upcoming quarterly results as the non-cash cost of these options will be amortized over the 4-year vesting period.

Jagsonpal Q1 FY27: PAT up 22% to ₹13.2 Cr; EBITDA Margins Expand to 23.2%

🟢 POSITIVE ⭐ 7/10

EARNINGS 📅 29 Jul 2026, 06:24 PM

Jagsonpal Pharmaceuticals reported a strong start to FY27 with Q1 revenue growing 8.8% YoY to ₹82.2 Cr, outperforming the Indian Pharmaceutical Market (IPM) growth. Profitability saw significant improvement as PAT rose 22.2% YoY to ₹13.2 Cr, supported by a 241 bps expansion in EBITDA margins to 23.2%. The company completed the 85% acquisition of Aequitas Healthcare, marking its entry into the hospital supplies segment. Despite a ₹40 Cr share buyback, the company remains cash-rich with ₹170 Cr in reserves.

Revenue grew 8.8% YoY to ₹82.2 Cr, with Pharmarack reporting 18.9% growth for the company vs 11.6% for the IPM.
Operating EBITDA increased 21.4% YoY to ₹19.1 Cr, driven by improved Medical Representative (MR) productivity.
PAT rose 22.2% YoY to ₹13.2 Cr, with net profit margins expanding by 176 bps to 16.0%.
Completed 85% acquisition of Aequitas Healthcare (revenue base ₹53.3 Cr) to enter the hospital business.
Maintained a robust cash balance of ₹170 Cr even after completing a ₹40 Cr share buyback during the quarter.

💡 Investors should monitor the integration of Aequitas Healthcare and its impact on margins, as management targets ₹10 Cr+ EBITDA from this segment by Year 2. Watch for the sustainability of the 23%+ EBITDA margins and the performance of the top 10 brands which contribute 63% of sales.

View All JAGSNPHARM Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Total revenue for H1 FY26 reached INR 150.1 Cr, a 10.2% YoY increase. Q2 FY26 revenue was INR 74.5 Cr, a marginal 0.3% YoY decline due to GST 2.0 transition adjustments. Key segments include Gynaecology, Orthopaedics, Dermatology, and Child-care, with Dydrogesterone growing from zero to INR 40 Cr within 18 months of launch.

Geographic Revenue Split

The company maintains an extensive pan-India distribution network; however, specific percentage splits by region are not disclosed in the available documents.

Profitability Margins

Net Profit Ratio improved significantly to 20.6% in FY 2024-25 from 10.8% in FY 2023-24. Q2 FY26 PAT margin expanded by 154 bps YoY to 16.9%, driven by improved business performance and operational efficiencies post-acquisition of Yash Pharma.

EBITDA Margin

Operating EBITDA margin (pre-ESOP) for Q2 FY26 stood at 24.3%, a slight 39 bps decline from 24.6% YoY. H1 FY26 Operating EBITDA grew 8.8% YoY to INR 33.8 Cr, reflecting efficient cost management and the successful integration of Yash Pharma's profitability to JPL levels.

Capital Expenditure

The company follows an asset-light model with minimal capital expenditure plans as it has transitioned to complete outsourcing of manufacturing operations to contract manufacturers.

Credit Rating & Borrowing

Long-term rating reaffirmed at [ICRA]BBB(Positive) and short-term rating upgraded to [ICRA]A2. The company maintains a robust financial risk profile with nil debt and a strong cash balance of INR 160.4 Cr as of September 30, 2025.

⚙️ Operational Drivers

Raw Materials

Specific chemical names are not disclosed; however, the company procures and supplies raw materials to a pool of contract manufacturers to maintain strict control over product quality.

Key Suppliers

The company utilizes a pool of third-party contract manufacturers rather than owning manufacturing plants, though specific vendor names are not listed.

Capacity Expansion

Current strategy focuses on 'complete outsourcing of manufacturing operations,' eliminating the need for owned capacity expansion. Growth is driven by brand acquisitions and new product launches rather than physical plant expansion.

Raw Material Costs

Raw material costs are managed by supplying inputs to contract manufacturers to mitigate quality risks. Trade payables increased in FY 2024-25 specifically due to the Yash Pharma business acquisition.

Manufacturing Efficiency

Efficiency is driven by an asset-light model. Inventory Turnover Ratio increased to 17.6 in FY 2024-25 from 13.9 in FY 2023-24, reflecting better inventory planning and control.

Logistics & Distribution

The company operates an extensive pan-India distribution network. Current Ratio decreased to 6.2 in FY 2024-25 from 9.5 in FY 2023-24 as surplus funds were utilized for the Yash Pharma acquisition.

📈 Strategic Growth

Expected Growth Rate

10.20%

Growth Strategy

Growth is targeted through a three-pronged strategy: 1) New product launches (e.g., Dydrogesterone), 2) Strategic acquisitions like Yash Pharma to expand the portfolio, and 3) Improving Medical Representative (MR) productivity to drive higher accretive value from existing fixed costs.

Products & Services

Pharmaceutical formulations in the form of medicines for Gynaecology, Orthopaedics, Dermatology, and Child-care segments.

Brand Portfolio

Divatrone, Maintane, J.P. Tone, Indocap, and Dydrogesterone.

New Products/Services

New product launches are a core driver; Dydrogesterone contributed ~15% of revenue (approx INR 40 Cr) within 18 months of its FY2022 launch.

Market Expansion

Expansion is focused on the Indian Pharmaceutical Market (IPM), which grew at 7.5% in Q2 FY26. JPL aims to outpace market growth through its 'double-engine' leadership and expanded portfolio.

Market Share & Ranking

Not disclosed as a specific percentage, but identified as a leading player with a 50+ year legacy in specialized segments like Gynaecology.

Strategic Alliances

The company acquired brands from Yash Pharma Private Limited (YPPL) in Q1 FY2025 for an estimated INR 93 Cr to strengthen its market position.

🌍 External Factors

Industry Trends

The Indian pharma market is growing at ~7.5%, driven by price increases. Trends show a shift toward high-margin products and increased regulatory scrutiny on manufacturing standards.

Competitive Landscape

Intense competition from contract manufacturers, MNCs, and established domestic brands, particularly affecting legacy brands like Divatrone and Maintane.

Competitive Moat

Moat is built on a 50-year brand legacy, a robust portfolio in niche segments (Gynaecology), and a strong pan-India distribution network. Sustainability is supported by an asset-light, high-liquidity financial model.

Macro Economic Sensitivity

Sensitive to Indian Pharmaceutical Market (IPM) trends and government healthcare policies like GST 2.0, which aims for affordable healthcare.

Consumer Behavior

Shift toward 'Patient First' approaches and affordable healthcare, influenced by government price reductions passed through GST 2.0.

Geopolitical Risks

The industry faces general regulatory trends and macro-economic condition changes, though JPL's focus is primarily domestic.

⚖️ Regulatory & Governance

Industry Regulations

Approximately 6-7% of revenues are subject to price control. The company must also comply with Ind AS and the Companies Act, 2013.

Taxation Policy Impact

The company transitioned to GST 2.0 in Q2 FY26, passing on price reduction benefits to patients, which caused a temporary moderation in sales.

Legal Contingencies

No material lapses or fraud were reported by internal auditors. The company has a 'Jagsonpal Pharmaceuticals Limited ESOP Plan 2022' in compliance with SEBI SBEBS Regulations.